益眼明口服液治疗肝肾阴虚型早期年龄相关性白内障的临床研究

Clinical Trial of Yiyanming Oral Liquid in Treating Early Age-related Cataract with Liver-kidney Yin Deficiency

目的评价益眼明口服液治疗肝肾阴虚型早期年龄相关性白内障的临床疗效。方法采用随机、平行、空白对照的方法,将肝肾阴虚型早期年龄相关性白内障患者118例(231眼)分为治疗组(59例117眼)和对照组(59例114眼)。治疗组口服益眼明口服液,对照组不服用任何药物,连续用药12周;观察用药前后视力、晶状体混浊程度、肝肾阴虚中医证候的变化。结果治疗前两组视力、晶状体混浊程度、中医证候评分比较差异无统计学意义(P>0.05);治疗后治疗组视力、中医证候的改善均明显优于对照组(P<0.05),治疗组总有效率为79.5%,明显优于对照组。结论益眼明口服液对肝肾阴虚型早期白内障患者有一定的治疗作用。

Objective To evaluate the clinical efficacy and safety of Yiyanming oral liquid in treating early agerelated cataract with liver-kidney yin deficiency. Methods A prospective, clinical randomized controlled trial was conducted. A total of 118 patients （involving 231 eyes） with liver-kidney yin deficiency early age-related cataract were randomly divided into two groups with clinical single blind method. Experimental group（59 patients, 117 eyes） were treated with Yiyanming oral liquid and the control group（59 patients, 114 eyes） were treated without any medicine. The therapeutic course lasted 12 weeks. After treatment, the efficacy and safety were evaluated. Results No obvious changes were found in visual acuity, fundus and ｜iver-kidney yin deficiency syndrome scores of in both groups before treatment （P 〉 0.05）. After treatment, the experimental group had better effect than control group on improving visual acuity and syndrome scores, and the difference was statistically significant（P 〈 0.05）. The total effective rate in the experimental group was 79.5 %. Conclusion Yiyanming oral liquid is effective and safe in treating early age-related cataract with liver-kidney yin deficiency.